Lunai Bioworks Inc.(LNAI)Earnings, Financials & Key Ratios
LNAI•NASDAQ
$0.33
$8M mkt cap·Price updated May 7, 2026
AboutA company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.Show more
- Revenue$0
- EBITDA-$18M+77.4%
- Net Income-$178M-101.3%
- EPS (Diluted)-10.78-18.5%
- ROE-321.81%-224.8%
- ROIC-22.39%+66.0%
- Interest Coverage-25.56+23.8%
LNAI Key Insights
Lunai Bioworks Inc. (LNAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 69.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LNAI Price & Volume
Lunai Bioworks Inc. (LNAI) stock price & volume — 10-year historical chart
Loading chart...
LNAI Growth Metrics
Lunai Bioworks Inc. (LNAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM21.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.54%
Return on Capital
10 Years-57.01%
5 Years-57.01%
3 Years-61.76%
Last Year-33.15%
LNAI Peer Comparison
Lunai Bioworks Inc. (LNAI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 TWST | 3.65B | 58.54 | -45.03 | 20.32% | -19.85% | -17.46% | 0.29 | |
 CDNA | 1.11B | 21.44 | -53.60 | 13.79% | -1.98% | -2.61% | 0.06 | |
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare LNAI vs Peers
Lunai Bioworks Inc. (LNAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LNAI Income Statement
Lunai Bioworks Inc. (LNAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 391.42K | 0 | 0 | 0 | 129.09K | 85.48K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -391.42K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -129.09K▲ 0% | -85.48K▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | - |
| Operating Expenses | 23.01M | 116.08M | 38.56M | 81.64M | 18.42M | 12.49M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 7.47M | 14.33M | 15.32M | 24.56M | 17.88M | 12.4M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 15.54M | 8.37M | 4.17M | 2.71M | 537.43K | 56.43K |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 93.38M | 19.07M | 54.37M | 0 | 31.98K |
| Operating Income | -23.4M▲ 0% | -116.08M▼ 396.0% | -38.56M▲ 66.8% | -81.64M▼ 111.7% | -18.55M▲ 77.3% | -12.58M▲ 0% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -396.03% | 66.78% | -111.74% | 77.28% | - |
| EBITDA | -23.01M | -115.96M | -38.44M | -81.52M | -18.42M | -12.46M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -403.93% | 66.85% | -112.05% | 77.41% | 89.43% |
| D&A (Non-Cash Add-back) | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K | 117.45K |
| EBIT | -26.47M | -113.06M | -38.98M | -85.99M | -18.55M | -8.04M |
| Net Interest Income | -366.43K | -250.8K | -706.96K | -2.43M | -609.34K | -679.9K |
| Interest Income | 13.18K | 122.04K | 0 | 0 | 116.35K | 7.01K |
| Interest Expense | 379.61K | 372.84K | 706.96K | 2.43M | 725.68K | 686.91K |
| Other Income/Expense | -3.45M | 2.65M | -1.13M | -6.79M | -159.46M | -112.95M |
| Pretax Income | -26.85M▲ 0% | -113.43M▼ 322.5% | -39.68M▲ 65.0% | -88.43M▼ 122.8% | -178.01M▼ 101.3% | -125.52M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | -125.28K | 34 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.47% | -0% | 0% | 0% | 0% | 0% |
| Net Income | -26.72M▲ 0% | -113.43M▼ 324.5% | -39.68M▲ 65.0% | -88.43M▼ 122.8% | -178.01M▼ 101.3% | -125.52M▲ 0% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -324.47% | 65.02% | -122.82% | -101.31% | 21.73% |
| Net Income (Continuing) | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M | -125.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.67▲ 0% | -21.60▼ 281.0% | -7.10▲ 67.1% | -9.10▼ 28.2% | -10.78▼ 18.5% | -5.35▲ 0% |
| EPS Growth % | - | -280.95% | 67.13% | -28.17% | -18.46% | 39.54% |
| EPS (Basic) | -5.67 | -21.60 | -7.10 | -9.10 | -10.78 | - |
| Diluted Shares Outstanding | 4.72M | 5.25M | 5.63M | 9.75M | 16.51M | 23.48M |
| Basic Shares Outstanding | 4.72M | 5.25M | 5.63M | 9.75M | 16.51M | 23.48M |
| Dividend Payout Ratio | - | - | - | - | - | - |
LNAI Balance Sheet
Lunai Bioworks Inc. (LNAI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 20.9M | 9.57M | 2.57M | 2M | 1.05M | 514.49K |
| Cash & Short-Term Investments | 20.66M | 9.17M | 1.87M | 220.47K | 480.55K | 491.64K |
| Cash Only | 20.66M | 9.17M | 1.87M | 220.47K | 92.7K | 491.64K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 387.85K | 0 |
| Accounts Receivable | 1.64K | 0 | 0 | 1.11M | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 393K | 690.92K | 668.93K | 566.08K | 22.84K |
| Total Non-Current Assets | 168.71M | 75.07M | 55.74M | 161.13M | 7.18M | 6.15M |
| Property, Plant & Equipment | 2.16M | 1.74M | 1.42M | 1.75M | 1.06M | 13.25K |
| Fixed Asset Turnover | - | - | - | - | - | 0.00x |
| Goodwill | 11.64M | 11.64M | 11.64M | 159.33M | 5.96M | 5.96M |
| Intangible Assets | 154.89M | 61.62M | 42.65M | 30.04K | 165.99K | 142.1K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 20.98K | 68.64K | 21.74K | 19.85K | 0 | 79.61K |
| Total Assets | 189.61M▲ 0% | 84.63M▼ 55.4% | 58.3M▼ 31.1% | 163.13M▲ 179.8% | 8.23M▼ 95.0% | 6.67M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x |
| Asset Growth % | - | -55.36% | -31.11% | 179.81% | -94.95% | -317.15% |
| Total Current Liabilities | 1.89M | 6.45M | 11.02M | 30.31M | 29.16M | 20M |
| Accounts Payable | 320.56K | 1.4M | 5.3M | 9.45M | 12.56M | 12.34M |
| Days Payables Outstanding | 298.93 | - | - | - | 35.5K | 52K |
| Short-Term Debt | 353.01K | 1.2M | 4.62M | 2.45M | 9.44M | 2.54M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.21M | 2.56M | 184.73K | 12.61M | 1.01M | 5.12M |
| Current Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x | 0.04x |
| Quick Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x | 0.04x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 13.06M | 5.56M | 775.59K | 842.39K | 424.55K | 213.66K |
| Long-Term Debt | 5.78M | 4.58M | 0 | 0 | 0 | 213.66K |
| Capital Lease Obligations | 1.24M | 985.7K | 775.59K | 842.39K | 424.55K | 1.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.04M | 0 | 0 | 0 | 0 | -213.66K |
| Total Liabilities | 14.94M | 12.01M | 11.8M | 31.15M | 29.58M | 20.22M |
| Total Debt | 7.37M | 7.02M | 5.59M | 3.79M | 10.17M | 2.97M |
| Net Debt | -13.29M | -2.16M | 3.72M | 3.57M | 10.08M | 2.48M |
| Debt / Equity | 0.04x | 0.10x | 0.12x | 0.03x | - | -0.22x |
| Debt / EBITDA | - | - | - | - | - | -0.24x |
| Net Debt / EBITDA | - | - | - | - | - | -0.20x |
| Interest Coverage | -61.65x | -311.33x | -54.54x | -33.53x | -25.56x | -11.70x |
| Total Equity | 174.66M▲ 0% | 72.62M▼ 58.4% | 46.5M▼ 36.0% | 131.98M▲ 183.8% | -21.35M▼ 116.2% | -13.55M▲ 0% |
| Equity Growth % | - | -58.42% | -35.96% | 183.81% | -116.18% | -380.22% |
| Book Value per Share | 37.03 | 13.82 | 8.26 | 13.53 | -1.29 | -0.58 |
| Total Shareholders' Equity | 174.66M | 72.62M | 46.5M | 131.98M | -21.35M | -13.55M |
| Common Stock | 5.22K | 5.3K | 6.37K | 15.85K | 17.74K | 2.42K |
| Retained Earnings | -90.91M | -204.35M | -244.03M | -332.46M | -510.46M | -509.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -10.83K | -30.44K | -29.88K | -170.85K | 10.81M | -139.02K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
LNAI Cash Flow Statement
Lunai Bioworks Inc. (LNAI) cash flow — operating, investing & free cash flow history
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -20.61M | -15.73M | -11.77M | -10.97M | -7.87M | -7.87M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | 23.67% | 25.16% | 6.82% | 28.23% | 159.73% |
| Net Income | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M | -125.52M |
| Depreciation & Amortization | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K | 117.45K |
| Stock-Based Compensation | 0 | 5.49M | 3.54M | 4.67M | 3.31M | 2.58M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.79M | 90.67M | 19.96M | 63.85M | 160.83M | 112.82M |
| Working Capital Changes | 932.13K | 1.42M | 4.31M | 8.81M | 5.86M | 4.29M |
| Change in Receivables | 342 | 1.59K | 46 | -1.11M | 1.15M | 156.65K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -272.32K | 1.08M | 3.89M | 4.06M | 3.11M | 2.4M |
| Cash from Investing | -48.89K | -5.16K | -29.77K | -1.26M | -500K | 43.46K |
| Capital Expenditures | -48.89K | -5.16K | -29.77K | -70.43K | 0 | -1.24K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -1.19M | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -1.46M |
| Cash from Financing | 32.6M | 4.25M | 4.52M | 10.52M | 8.38M | 6.06M |
| Debt Issued (Net) | -546.65K | -560.85K | 0 | 8.05M | 6.98M | 2.85M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 750K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.22M | 134.91K | 503.23K | -528.21K | -971.23K | 2.46M |
| Net Change in Cash | 11.97M▲ 0% | -11.49M▼ 196.0% | -7.3M▲ 36.5% | -1.65M▲ 77.3% | -127.77K▲ 92.3% | 179.88K▲ 0% |
| Free Cash Flow | -20.66M▲ 0% | -15.74M▲ 23.8% | -11.8M▲ 25.0% | -11.04M▲ 6.5% | -7.87M▲ 28.7% | -5.72M▲ 0% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | 23.82% | 24.99% | 6.46% | 28.68% | 40.74% |
| FCF per Share | -4.38 | -3.00 | -2.10 | -1.13 | -0.48 | -0.48 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.14x | 0.30x | 0.12x | 0.04x | 0.05x |
| Interest Paid | 0 | 79.72K | 352.33K | 20.13K | 24.55K | 25.68K |
| Taxes Paid | 0 | 34 | 0 | 0 | 0 | 0 |
LNAI Key Ratios
Lunai Bioworks Inc. (LNAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -91.74% | -66.63% | -99.09% | -321.81% | -1241.35% |
| Return on Invested Capital (ROIC) | -75.11% | -47.92% | -65.92% | -22.39% | -22.39% |
| Debt / Equity | 0.10x | 0.12x | 0.03x | - | -0.22x |
| Interest Coverage | -311.33x | -54.54x | -33.53x | -25.56x | -11.70x |
| FCF Conversion | 0.14x | 0.30x | 0.12x | 0.04x | 0.05x |
LNAI Frequently Asked Questions
Lunai Bioworks Inc. (LNAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lunai Bioworks Inc. (LNAI) grew revenue by 0.0% over the past year. Growth has been modest.
Lunai Bioworks Inc. (LNAI) reported a net loss of $125.5M for fiscal year 2024.
Dividend & Returns
Lunai Bioworks Inc. (LNAI) has a return on equity (ROE) of -321.8%. Negative ROE indicates the company is unprofitable.
Lunai Bioworks Inc. (LNAI) had negative free cash flow of $5.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More LNAI
Lunai Bioworks Inc. (LNAI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates